Kodiak Sciences Overview
- Year Founded
-
2009
- Status
-
Public
- Employees
-
108
- Stock Symbol
-
KOD
- Share Price
-
$5.26
- (As of Friday Closing)
Kodiak Sciences General Information
Description
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is KSI-301, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD.
Contact Information
Website
www.kodiak.comCorporate Office
- 1200 Page Mill Road
- Palo Alto, CA 94304
- United States
Corporate Office
- 1200 Page Mill Road
- Palo Alto, CA 94304
- United States
Kodiak Sciences Stock Performance
As of 14-Feb-2025, Kodiak Sciences’s stock price is $5.26. Its current market cap is $277M with 52.6M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $5.26 | $5.10 | $2.19 - $11.60 | $277M | 52.6M | 446K | -$3.64 |
Kodiak Sciences Financials Summary
As of 30-Sep-2024, Kodiak Sciences has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | (6,144) | (102,676) | (75,031) | 3,664,302 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (177,845) | (258,911) | (337,076) | (258,530) |
| Net Income | (191,618) | (260,491) | (333,823) | (266,990) |
| Total Assets | 372,669 | 479,372 | 666,628 | 904,220 |
| Total Debt | 73,435 | 81,632 | 87,733 | 79,996 |
Kodiak Sciences Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Kodiak Sciences Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Kodiak Sciences Comparisons
Industry
Financing
Details
Kodiak Sciences Competitors (31)
One of Kodiak Sciences’s 31 competitors is Larimar Therapeutics, a Formerly VC-backed company based in Bala Cynwyd, PA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Larimar Therapeutics | Formerly VC-backed | Bala Cynwyd, PA | ||||
| Achaogen | Formerly VC-backed | South San Francisco, CA | ||||
| Alnylam Pharmaceuticals | Formerly VC-backed | Cambridge, MA | ||||
| Design Therapeutics | Formerly VC-backed | Carlsbad, CA | ||||
| EyePoint Pharmaceuticals | Corporation | Watertown, MA |
Kodiak Sciences Patents
Kodiak Sciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20230250133-A1 | Methods of purifying a product | Pending | 10-Feb-2022 | ||
| AU-2023217074-A1 | Methods of purifying a product | Pending | 10-Feb-2022 | ||
| EP-4476237-A2 | Methods of purifying a product | Pending | 10-Feb-2022 | ||
| EP-4323399-A1 | Methods of treating an eye disorder | Pending | 14-Apr-2021 | ||
| US-20240238427-A1 | Methods of treating an eye disorder | Pending | 14-Apr-2021 | A61K47/56 |
Kodiak Sciences Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Kodiak Sciences ESG
Risk Overview
Risk Rating
Updated March, 01, 2024
25.53 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,120
Rank
Percentile
Pharmaceuticals
Industry
of 853
Rank
Percentile
Biotechnology
Subindustry
of 368
Rank
Percentile
Kodiak Sciences FAQs
-
When was Kodiak Sciences founded?
Kodiak Sciences was founded in 2009.
-
Where is Kodiak Sciences headquartered?
Kodiak Sciences is headquartered in Palo Alto, CA.
-
What is the size of Kodiak Sciences?
Kodiak Sciences has 108 total employees.
-
What industry is Kodiak Sciences in?
Kodiak Sciences’s primary industry is Pharmaceuticals.
-
Is Kodiak Sciences a private or public company?
Kodiak Sciences is a Public company.
-
What is Kodiak Sciences’s stock symbol?
The ticker symbol for Kodiak Sciences is KOD.
-
What is the current stock price of Kodiak Sciences?
As of 14-Feb-2025 the stock price of Kodiak Sciences is $5.26.
-
What is the current market cap of Kodiak Sciences?
The current market capitalization of Kodiak Sciences is $277M.
-
Who are Kodiak Sciences’s competitors?
Larimar Therapeutics, Achaogen, Alnylam Pharmaceuticals, Design Therapeutics, and EyePoint Pharmaceuticals are some of the 31 competitors of Kodiak Sciences.
-
What is Kodiak Sciences’s annual earnings per share (EPS)?
Kodiak Sciences’s EPS for 12 months was -$3.64.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
